Retreatment With Varenicline for Smoking Cessation in Smokers Who Have Previously Taken Varenicline: A Randomized, Placebo-Controlled Trial
| Autor: | L-J Tseng, J Treadow, Kristiaan Nackaerts, David Gonzales, Thomas McRae, L Pliamm, Peter Hajek |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Counseling
Male Time Factors medicine.medical_treatment Placebo-controlled study Smoking Prevention law.invention chemistry.chemical_compound Randomized controlled trial Recurrence law Odds Ratio Medicine Pharmacology (medical) Nicotinic Agonists Varenicline media_common Smoking Tobacco Use Disorder Articles Middle Aged Europe Treatment Outcome Retreatment Female Adult Canada medicine.medical_specialty media_common.quotation_subject Placebo Young Adult Double-Blind Method Quinoxalines Multicenter trial Internal medicine Humans Psychiatry Adverse effect Aged Pharmacology Chi-Square Distribution business.industry Australia Benzazepines Abstinence United States chemistry Smoking cessation Smoking Cessation business |
| Zdroj: | Clinical Pharmacology and Therapeutics |
| ISSN: | 1532-6535 0009-9236 |
| Popis: | The efficacy and safety of retreatment with varenicline in smokers attempting to quit were evaluated in this randomized, double-blind, placebo-controlled, multicenter trial (Australia, Belgium, Canada, the Czech Republic, France, Germany, the United Kingdom, and the United States). Participants were generally healthy adult smokers (≥ 10 cigarettes/day) with ≥ 1 prior quit attempt (≥ 2 weeks) using varenicline and no quit attempts in ≤ 3 months; they were randomly assigned (1:1) to 12 weeks' varenicline (n = 251) or placebo (n = 247) treatment, with individual counseling, plus 40 weeks' nontreatment follow-up. The primary efficacy end point was the carbon monoxide-confirmed (≤ 10 ppm) continuous abstinence rate for weeks 9-12, which was 45.0% (varenicline; n = 249) vs. 11.8% (placebo; n = 245; odds ratio: 7.08; 95% confidence interval: 4.34, 11.55; P < 0.0001). Common varenicline group adverse events were nausea, abnormal dreams, and headache, with no reported suicidal behavior. Varenicline is efficacious and well tolerated in smokers who have previously taken it. Abstinence rates are comparable with rates reported for varenicline-naive smokers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text